Literature DB >> 32030298

Neoadjuvant vs. adjuvant chemotherapy in locally advanced non-small cell lung cancer-is timing everything?

Melanie P Subramanian1, Varun Puri1.   

Abstract

Entities:  

Year:  2019        PMID： 32030298      PMCID： PMC6988026          DOI： 10.21037/jtd.2019.12.40

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  8 in total

Review 1.  Adjuvant or neoadjuvant chemotherapy for NSCLC.

Authors:  Philip McElnay; Eric Lim
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

2.  Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.

Authors:  Whitney S Brandt; Wanpu Yan; Jian Zhou; Kay See Tan; Joseph Montecalvo; Bernard J Park; Prasad S Adusumilli; James Huang; Matthew J Bott; Valerie W Rusch; Daniela Molena; William D Travis; Mark G Kris; Jamie E Chaft; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2018-10-10       Impact factor: 5.209

3.  Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.

Authors:  Enriqueta Felip; Rafael Rosell; José Antonio Maestre; José Manuel Rodríguez-Paniagua; Teresa Morán; Julio Astudillo; Guillermo Alonso; José Manuel Borro; José Luis González-Larriba; Antonio Torres; Carlos Camps; Ricardo Guijarro; Dolores Isla; Rafael Aguiló; Vicente Alberola; José Padilla; Abel Sánchez-Palencia; José Javier Sánchez; Eduardo Hermosilla; Bartomeu Massuti
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

Review 4.  Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials.

Authors:  Eric Lim; Grace Harris; Amit Patel; Iki Adachi; Lyn Edmonds; Fujian Song
Journal:  J Thorac Oncol       Date:  2009-11       Impact factor: 15.609

5.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

6.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.

Authors:  David S Ettinger; Dara L Aisner; Douglas E Wood; Wallace Akerley; Jessica Bauman; Joe Y Chang; Lucian R Chirieac; Thomas A D'Amico; Thomas J Dilling; Michael Dobelbower; Ramaswamy Govindan; Matthew A Gubens; Mark Hennon; Leora Horn; Rudy P Lackner; Michael Lanuti; Ticiana A Leal; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Sandip P Patel; Karen Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; James Stevenson; Scott J Swanson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2018-07       Impact factor: 11.908

7.  Outcomes of neoadjuvant and adjuvant chemotherapy in stage 2 and 3 non-small cell lung cancer: an analysis of the National Cancer Database.

Authors:  Matthew MacLean; Xin Luo; Shidan Wang; Kemp Kernstine; David E Gerber; Yang Xie
Journal:  Oncotarget       Date:  2018-05-11

Review 8.  Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.

Authors: 
Journal:  Lancet       Date:  2014-02-25       Impact factor: 79.321
  8 in total
  1 in total

1.  Downregulation of ARID1A is correlated with poor prognosis in non-small cell lung cancer.

Authors:  Tao Wang; Jinyan Guo; Wenhua Liu; Qi Guo; Lvhuan Cheng; Renshan Zheng; Xinchun Hu
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.